Patritumab deruxtecan trials for Breast Neoplasms

All Patritumab deruxtecan trials · All Breast Neoplasms trials

Phase breakdown

Recruiting trials studying Patritumab deruxtecan for Breast Neoplasms

• A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  NCT07060807 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 199 locations
• Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
  NCT06797635 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
  NCT06686394 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations

Common questions

How many trials study Patritumab deruxtecan for Breast Neoplasms?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.